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Microvascular invasion in hepatocellular carcinoma:  
is it predictable with quantitative computed tomography 
parameters?
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Abstract
Resumo
Objective: To investigate whether quantitative computed tomography (CT) measurements can predict microvascular invasion (MVI) 
in hepatocellular carcinoma (HCC).
Materials and Methods: This was a retrospective analysis of 200 cases of surgically proven HCCs in 125 consecutive patients 
evaluated between March 2010 and November 2017. We quantitatively measured regions of interest in lesions and adjacent areas 
of the liver on unenhanced CT scans, as well as in the arterial, portal venous, and equilibrium phases on contrast-enhanced CT 
scans. Enhancement profiles were analyzed and compared with histopathological references of MVI. Univariate and multivariate 
logistic regression analyses were used in order to evaluate CT parameters as potential predictors of MVI.
Results: Of the 200 HCCs, 77 (38.5%) showed evidence of MVI on histopathological analysis. There was no statistical difference 
between HCCs with MVI and those without, in terms of the percentage attenuation ratio in the portal venous phase (114.7 vs. 115.8) 
and equilibrium phase (126.7 vs. 128.2), as well as in terms of the relative washout ratio, also in the portal venous and equilibrium 
phases (15.0 vs. 8.2 and 31.4 vs. 26.3, respectively).
Conclusion: Quantitative dynamic CT parameters measured in the preoperative period do not appear to correlate with MVI in HCC.
Keywords: Carcinoma, hepatocellular; Tomography, X-ray computed; Liver neoplasms/surgery; Liver transplantation.
Objetivo: O objetivo deste estudo foi investigar se parâmetros quantitativos da tomografia computadorizada (TC) podem predizer 
invasão microvascular (IMV) no carcinoma hepatocelular (CHC).
Materiais e Métodos: Foram analisados, retrospectivamente, 200 CHCs comprovados de 125 pacientes submetidos consecutiva-
mente a transplante ou ressecção hepática entre março/2010 e novembro/2017. Foram realizadas medidas quantitativas da den-
sidade das lesões e do parênquima hepático adjacente pré-contraste e nas fases arterial, portal e de equilíbrio das TCs. Parâmetros 
de impregnação foram comparados com a presença de IMV nos laudos anatomopatológicos. Regressões logísticas univariadas e 
multivariadas foram utilizadas para avaliar os parâmetros da TC como potenciais preditores de IMV.
Resultados: Dos 200 CHCs, 77 (38,5%) tinham IMV no anatomopatológico. Não houve diferença estatística na razão de atenuação 
entre CHCs com IMV e os sem IMV na fase portal (114,7 para IMV positiva e 115,8 para IMV negativa) ou de equilíbrio (126,7 para 
IMV positiva e 128,2 para IMV negativa), nem na razão de washout relativa nas fases portal e de equilíbrio (15,0 para IMV positiva 
e 8,2 para IMV negativa na fase portal, e 31,4 para IMV positiva e 26,3 para IMV negativa na fase de equilíbrio).
Conclusão: Não houve relação entre os parâmetros quantitativos da TC pré-operatória e IMV dos CHCs.
Unitermos: Carcinoma hepatocelular; Tomografia computadorizada; Neoplasias hepáticas/cirurgia; Transplante de fígado.
invasion (MVI) has been reported to be one of the most 
significant independent risk factors affecting recurrence-
free survival and a major risk factor for a poor outcome 
following partial hepatic resection or liver transplantation 
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
frequently diagnosed cancers and a leading cause of cancer-
related death worldwide(1). The presence of microvascular 
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in HCC patients within the Milan criteria(2,3). Therefore, 
predicting MVI preoperatively could allow appropriate pa-
tient selection for each treatment.
As the technology has evolved, imaging has come to 
play an increasingly more important role in HCC evalu-
ation. Triphasic dynamic multidetector computed tomog-
raphy (CT), which includes arterial, portal venous, and 
equilibrium phases, is considered to be the primary ap-
proach for the diagnosis of HCC worldwide. In comparison 
with the background liver parenchyma, the typical HCC 
is hyperdense in the arterial phase (arterial hyperenhance-
ment), isodense or hypodense in the portal venous phase, 
and hypodense in the equilibrium phase, hypodensity also 
being referred to as washout appearance(4,5).
The identification of arterial hyperenhancement and 
washout appearance is based solely on the visual (subjec-
tive) assessment. As has been proposed by some authors(6), 
quantitative measurement of these phenomena would re-
duce the chances of misinterpretation, thus avoiding incor-
rect diagnosis and inappropriate patient management.
The aim of this study was to determine whether quan-
titative measurements of dynamic CT could be useful in 
predicting MVI in HCC. To that end, we reviewed such 
measurements in a group of patients with HCC.
MATERIALS AND METHODS
Patient selection
We retrospectively reviewed 161 consecutive patients 
(238 lesions) who underwent liver transplantation or surgi-
cal hepatic resection between March 2010 and November 
2017 and had surgically proven HCC. All of the patients 
evaluated had been submitted to a dedicated triphasic CT 
liver protocol within the last six months before surgery.
Patients who had no previous CT study on file at our 
institution were excluded, as were those in whom the CT 
study was incomplete (unenhanced or biphasic CT only), 
those submitted to chemoembolization prior to surgery, 
and those diagnosed with a combination of HCC and chol-
angiocarcinoma. Thus, we included 200 lesions in 125 pa-
tients (98 men, 27 women; mean age, 59 years; age range, 
36–81 years). Of those 125 patients, 72 (57.6%) had hepa-
titis C, 11 (8.8%) had hepatitis B, 5 (4.0%) had coinfec-
tion with hepatitis C and hepatitis B, and 20 (16.0%) had 
cryptogenic cirrhosis.
All procedures were conducted in accordance with the 
principles of the Declaration of Helsinki, and the study was 
approved by the local institutional review board. The re-
quirement for informed consent was waived.
Pathology
The specimens and liver explants were fixed in 10% for-
malin and embedded in paraffin. Three- to five-micrometer 
sections were affixed to slides, deparaffinized, and stained 
with hematoxylin and eosin. All slides were examined by a 
senior hepatopathologist.
Liver CT technique
All studies were performed in a 16-slice multidetec-
tor CT scanner (BrightSpeed 16; GE Healthcare, Milwau-
kee, WI, USA) or in a 64-slice multidetector CT scanner 
(Aquilion 64; Toshiba Medical Systems, Tochigi, Japan). 
Typically, 120 mL (or less for patients with low weight) of 
contrast material (Henetix 300 [iobitridol, 300 mg I/mL]; 
Guerbet, Sulzbach, Germany, or Omnipaque 300 [ioexol, 
300 mg I/mL]; GE Healthcare, Amersham, UK) were power 
injected intravenously at a rate of 4–5 mL/s, and that was 
followed by a saline flush. No contrast medium was ad-
ministered orally or rectally. Images were acquired prior 
to contrast administration, as well as in the arterial phase 
(10–15 s after peak abdominal aortic enhancement), por-
tal venous phase (80 s after intravenous contrast injec-
tion), and equilibrium phase (180 s after intravenous con-
trast injection). Bolus tracking software (SmartPrep; GE 
Healthcare, or SureStart; Toshiba Medical Systems) was 
used. The scanning parameters were 1.0–1.25 mm section 
collimation and a 3.0-mm reconstruction interval.
Image analysis
An abdominal radiologist with 11 years of experience, 
who was blinded to the pathology results, reviewed all of 
the imaging studies. On the arterial-, portal venous-, and 
equilibrium-phase images, circular or oval regions of in-
terest (ROIs) were manually drawn over the lesion, as well 
as over two adjacent areas of the liver, and Hounsfield 
units were measured. In heterogeneous lesions, the area 
with the most significant arterial hyperenhancement was 
considered for analysis, together with the corresponding 
portal venous and equilibrium phase measurements for 
that area. Care was taken to avoid any blood vessels, bili-
ary ducts, or artifacts. The CT values for the two ROIs 
drawn over the adjacent areas of the liver were averaged.
The attenuation difference was defined as the differ-
ence between the attenuation of lesion and that of the 
adjacent areas of the liver and was calculated in all three 
phases (arterial, portal venous, and equilibrium). The per-
centage attenuation ratio (PAR), attenuation difference, 
and relative washout ratio (RWR) for the portal venous and 
equilibrium phases were calculated as follows: 
PARPV/E = 100 × (AAPV/E/LAPV/E)
ADPV/E = (AAPV/E − LAPV/E)
RWRPV/E = 100 × (LAA − LAPV/E)/LAA
where PARPV/E is the PAR in the portal venous phase (PV) 
or equilibrium phase (E); AAPV/E is the average of the two 
areas adjacent to the lesion (AA) in the PV or E; LAPV/E is 
the attenuation of the lesion (LA) in the PV or E; ADPV/E 
is the attenuation difference in the PV or E; RWRPV/E is 
the RWR in the PV or E; and LAA is the LA in the arterial 
phase (A). All attenuation measurements were expressed in 
Hounsfield units. Figure 1 demonstrates a representative, 
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surgically proven HCC in the arterial, portal venous, and 
equilibrium phases, with attenuation measurements.
Data analysis and statistics
Generalized estimating equations and a logistic regres-
sion model with correlated data analysis were used for the 
univariate analysis. No variables were sufficiently signifi-
cant to be included in a multivariate analysis. To identify 
the independent predictors of MVI among the CT param-
eters, we constructed a receiver operating characteristic 
curve for repeated measures analysis of variance. Statis-
tical analyses were performed with the SAS System for 
Windows, version 9.4 (SAS Institute Inc.; Cary, NC, USA). 
Values of p < 0.05 were considered statistically significant. 
RESULTS
We collected CT data for 161 patients with surgically 
proven HCC (238 lesions). Thirty-six patients (38 lesions) 
were excluded from the analysis, either because they did 
not meet the study criteria or because the data were in-
complete. Therefore, the final sample comprised 200 le-
sions in 125 patients. The mean lesion size was 3.0 cm 
(range, 1.0–25.0 cm; median 2.2 cm). Of the 125 patients, 
69 (55.2%) had one lesion and 56 (44.8%) had two or more 
(range 2–6; median, 2.9). In the histopathological analysis, 
MVI was found in 77 (38.5%) of the 200 lesions evaluated.
In the subjective analysis, 179 (89.5%) of the HCCs 
showed arterial hyperenhancement (i.e., were hypervas-
cular), 127 (63.5%) showed washout in the portal venous 
phase and 194 (97.0%) showed washout only in the equi-
librium phase. Figure 2 shows the distribution of attenua-
tion values of HCCs and of the adjacent areas of the liver 
in the arterial, portal venous, and equilibrium phases, in 
lesions with and without MVI.
To depict the dynamics of HCCs with greater preci-
sion, quantitative enhancement profiles were assessed. 
The first of such profiles was assessed by calculating the 
PAR for each lesion in the portal venous and equilibrium 
phases. There was no statistically significant difference 
in the PAR between the HCCs with MVI and those with-
out, in the portal venous phase (median PAR, 114.7 and 
115.8, respectively) or in the equilibrium phase (median 
PAR, 126.7 and 128.2, respectively). Another quantitative 
enhancement profile was assessed by calculating the RWR 
Figure 1. HCC. Unenhanced CT image (A), together with CT images obtained in the arterial phase (B), portal venous phase (C), and equilibrium phase (D), with ROIs 
positioned over the lesion and over two areas of the adjacent liver parenchyma.
A B
C D
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(defined as 100 × the ratio between the lesion attenuation 
in the arterial phase and that observed in the subsequent 
phase) for each lesion. In terms of the RWR, there was 
no statistically significant difference between the HCCs 
with MVI and those without, in the portal venous phase 
(median RWR, 15.0 and 8.2, respectively) or in the equi-
librium phase (median RWR, 31.4 and 26.3, respectively). 
The third enhancement profile assessed was the attenua-
tion difference (defined as the difference between the at-
tenuation of lesion and the average attenuation of the two 
adjacent areas of the liver parenchyma). Again, there was 
no statistically significant difference between the HCCs 
with MVI and those without, in the arterial phase (median 
attenuation difference, 35.2 and 29.6, respectively), por-
tal venous phase (median attenuation difference, −8.5 and 
−8.3, respectively), or equilibrium phase (median attenua-
tion difference, −14.5 and −14.8, respectively).
Table 1 shows a descriptive analysis of all of the pa-
rameters studied. Table 2 shows the results of the uni-
variate logistic regression of the factors studied to dis-
criminate MVI. Table 3 shows a comparative analysis of 
all quantitative CT enhancement profiles in patients with 
and without MVI.
DISCUSSION
MVI is frequently described as a major risk factor for 
a poor outcome in patients with HCC submitted to liver 
Figure 2. Box plot showing the distribution of attenuation values of HCCs with MVI (MVI HCC) and without MVI (non-MVI HCC) in the arterial, portal venous, and 
equilibrium phases.
Table 1—Descriptive analysis and comparison between the presence or ab-
sence of MVI.
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transplantation or surgical hepatic resection(2,7–10). MVI is 
beyond the limits of imaging resolution and therefore can-
not be directly visualized with current imaging methods.
Contrast-enhanced CT is a relatively simple, noninva-
sive method that is widely used in order to evaluate patients 
with HCC in routine clinical practice. Almost all patients 
who will be submitted to liver transplantation or hepatic 
resection undergo a preoperative CT scan. Therefore, it 
would be reasonable to identify biomarkers from a relative 
simple method such as contrast-enhanced CT.
In the present study, we investigated the correlation 
between quantitative contrast-enhanced CT parameters 
and MVI in pathologically proven HCCs. We found that 
none of the quantitative CT parameters evaluated were 
predictive of MVI in patients with HCC submitted to cura-
tive surgical treatment.
Although MVI in HCC is one of the most important 
predictors of recurrence and survival after liver transplan-
tation or hepatic resection, it is difficult to identify MVI 
through imaging studies. A number of biomarkers have 
been tested in attempts to predict MVI, some producing 
contradictory or inconclusive results(11–13). Morphological 
criteria, such as the presence of internal arteries or tu-
mor necrosis, have been associated with MVI(14). Pawlik et 
al.(15) found that an HCC diameter > 5 cm should be con-
sidered a poor prognostic factor because of the high inci-
dence of MVI among such lesions. Chandarana et al.(16) 
found tumor multifocality to correlate with MVI. Chou 
et al.(17) and Lim et al.(18) showed that the absence of a 
capsule, invasion of the capsule, and an irregular tumor 
margin all correlate positively with MVI. However, Miyata 
et al.(19) found that the presence or absence of a capsule 
did not correlate with MVI.
Magnetic resonance imaging (MRI) is another impor-
tant method for the diagnosis of HCC(20–23). Some func-
tional MRI parameters, especially those determined with 
diffusion-weighted imaging (DWI), have also been investi-
gated as potential predictors of outcomes in patients with 
HCC. Xu et al.(24) demonstrated that HCCs with MVI have 
lower apparent diffusion coefficient (ADC) values on DWI 
than do those without MVI, showing that the ADC value, 
at a cutoff of 1.227 × 10−3 mm2/s, has a sensitivity and 
specificity of 66.7% and 78.6%, respectively, for detecting 
small HCCs. Suh et al.(25) showed that the ADC value, at 
a cutoff of 1.11 × 10−3 mm2/s, has a sensitivity of 93.5% 
and a specificity of 72.2% for the prediction of MVI. Yang 
et al.(26) proposed a biomarker based on the relationship 
between DWI and T2-weighted MRI sequences, specifi-
cally a DWI/T2 mismatch, and found it to have a high 
specificity (95.6%) but a very low sensitivity (18.1%) for 
the prediction of MVI in HCC. Kim et al.(27) reported that 
a hypointense signal in the region surrounding a tumor in 
the hepatobiliary phase of gadoxetate disodium-enhanced 
MRI has a high specificity but low sensitivity for predict-
ing MVI in HCC. Lee et al.(28) found that combining that 
condition with arterial peritumoral enhancement, a non-
smooth tumor margin, or both had a specificity > 90% for 
predicting MVI in HCC. However, Kim et al.(12) showed 
that the probability of MVI was low in HCCs showing an 
isointense or hyperintense signal on gadoxetate disodium-
enhanced MRI.
The expression of certain CT biomarkers, such as 
those based on texture analysis, has also been proposed as 
a predictor of MVI in HCC, producing promising results in 
a few studies(29,30). However, further studies of such bio-
markers are needed.
Our study has some limitations. The retrospective na-
ture of the study could have introduced a detection bias. 
In addition, there are some technical limitations, such as 
a lack of optimization of the dose of contrast medium in 
relation to body weight, the fact that the images were ac-
quired in two different CT scanners (although the techni-
cal parameters were similar), and the fact that our results 
depended on the ROIs being drawn correctly. Further-
more, we did not take into consideration certain clinical 
criteria, such as the Child-Pugh classification, which can 
be associated with changes in liver perfusion. Moreover, 









































95% CI, 95% confidence interval.
Table 3—Comparative analysis of quantitative CT enhancement profiles in HCC 
patients with and without MVI.
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we did not assess the histological grade of the HCCs, nor 
did we evaluate a method that allows objective assessment 
of a lesion and its heterogeneity, such as texture analysis. 
Finally, we assessed HCCs only on the basis of the pres-
ence or absence of MVI. In one recent study, patients were 
further categorized into different grades of MVI, based on 
the number of vessels involved(3). Therefore, further stud-
ies are warranted in order to determine the true applicabil-
ity of CT biomarkers as predictors of MVI.
In conclusion, although CT is the most widely used 
method and plays an important role in the evaluation of pa-
tients who will undergo HCC resection or liver transplanta-
tion, it has certain limitations in predicting MVI. This study 
highlights those limitations, showing that the proposed 
quantitative approach is not useful for achieving that goal.
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